Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease

Ito, Emi; Oka, Ritsuko; Ishii, Takeo; Korekane, Hiroaki; Kurimoto, Ayako; Kizuka, Yasuhiko; Kitazume, Shinobu; Ariki, Shigeru; Takahashi, M.; Kuroki, Yoshio; Kida, Kenji; Taniguchi, Naoyuki

doi:10.1016/j.jprot.2015.07.011

Cited by 27 publications

(22 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, a depletion of core‐fucose content may change the proteins' hydrophilicity and automatically affect their cellular localization . Illustrative cases of immune alterations due to increased fucosylation are: (a) the discovery of the hyperfucosylated surfactant protein D—a protein that impacts the immune response of the respiratory tract—as a biomarker of chronic obstructive pulmonary disease; and (b) the association between TCR and other T cell proteins core‐fucosylation, inflammatory cytokines production and colitis onset in mice and humans …”

Section: Discussionmentioning

confidence: 99%

CDG and immune response: From bedside to bench and back

Pascoal

Francisco

Ferro

et al. 2019

J of Inher Metab Disea

View full text Add to dashboard Cite

Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein‐attached glycans that mediate cell‐cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life‐threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF‐β1, NFAT, and NF‐κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3‐CDG and SLC35C1‐CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

CDG and immune response: From bedside to bench and back

Pascoal

Francisco

Ferro

et al. 2019

J of Inher Metab Disea

View full text Add to dashboard Cite

show abstract

“…Az SPD N-glikánjainak centrális fukozilációja szignifikánsan magasabb volt dohányos COPD-sekben, mint dohányos nem COPDsekben. Az emphysema mértéke arányos volt a centrális fukoziláció mértékével, ami arra utalhat, hogy az SPD centrális fukozilációja összefüggésben állhat az emphysema kialakulásával, és alkalmas prognosztikus marker lehet a COPD kialakulási hajlamának megítélésére [36].…”

Section: A Copd Közelmúltban Felfedezett Glikán Biomarkereiunclassified

Protein és glikán biomarkerek szerepe a krónikus obstruktív tüdőbetegség diagnosztikájában

Szabó

Kun

Hajba

et al. 2020

View full text Add to dashboard Cite

Absztrakt: A krónikus obstruktív tüdőbetegség (COPD) világszerte előkelő helyet foglal el a morbiditási és mortalitási statisztikákban. A COPD megelőzhető és kezelhető betegség, kialakulásáért döntően a dohányzás tehető felelőssé. A prevenció kulcsfontosságú, de korlátozottan kivitelezhető, így a rizikó meghatározása és a korai noninvazív diagnosztika révén lehetne tovább csökkenteni a COPD miatti halálozást. A fejlődő diagnosztikus technikák ellenére az optimális szűrővizsgálat felfedezése még várat magára. Kellően szenzitív és specifikus biomarkerek felfedezése megfelelő eszközt adhat a klinikus kezébe a betegség korai diagnosztizálásához, a differenciáldiagnosztikához, a fenotipizáláshoz és a prognózis becsléséhez. Közleményünkben a COPD vonatkozásában a közelmúltban felfedezett potenciális fehérje és glikán biomarkereket foglaljuk össze. Orv Hetil. 2020; 161(4): 123–128.

show abstract

“…Based on the assumption that an aberrant glycosylation is closely associated with the pathogenesis of various human diseases, the role played by the N‐glycosylation of surfactant protein D (SP‐D), a lung‐specific glycoprotein, was investigated by Ito et al . To determine whether changes in N‐glycosylation patterns of serum SP‐D could have a diagnostic value suggestive of COPD development, enriched SP‐D serum samples from healthy never‐smokers, smokers and stable COPD patients were submitted to proteomic analysis based on MALDI‐Qit‐TOF MS.…”

Section: Biological Fluidsmentioning

confidence: 99%

Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state

et al. 2018

View full text Add to dashboard Cite

Detection of proteins which may be potential biomarkers of disorders represents a big step forward in understanding the molecular mechanisms that underlie pathological processes. In this context proteomics plays the important role of opening a path for the identification of molecular signatures that can potentially assist in early diagnosis of several clinical disturbances. Aim of this report is to provide an overview of the wide variety of proteomic strategies that have been applied to the investigation of chronic obstructive pulmonary disease (COPD), a severe disorder that causes an irreversible damage to the lungs and for which there is no cure yet. The results in this area published over the past decade show that proteomics indeed has the ability of monitoring alterations in expression profiles of proteins from fluids/tissues of patients affected by COPD and healthy controls. However, these data also suggest that proteomics, while being an attractive tool for the identification of novel pathological mediators of COPD, remains a technique mainly generated and developed in research laboratories. Great efforts dedicated to the validation of these biological signatures will result in the proof of their clinical utility.

show abstract

Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease

Cited by 27 publications

References 47 publications

CDG and immune response: From bedside to bench and back

CDG and immune response: From bedside to bench and back

Protein és glikán biomarkerek szerepe a krónikus obstruktív tüdőbetegség diagnosztikájában

Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state

Contact Info

Product

Resources

About